in preventing the release of TNF-α and other inflammatory cytokines such as IL–1β.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 90 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 22, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–22076 Filed 8–28–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: ''Antiprogestins With Partial Agonist Activity

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of an exclusive license worldwide to practice the invention embodied in: U.S. Patent Application Serial No. 60/192,039, filed March 24, 2000, now converted into PCT application number PCT/US01/09395 filed March 23, 2001 entitled, ''Antiprogestins with Partial Agonist Activity'' to Dimera Inc., having a place of business in the state of Oregon. The field of use may be limited to anti-anginal protection/therapy and female reproduction therapies. The United States of America is the assignee of the patent rights in this invention.

DATES: Only written comments and/or application for a license, which are received by the NIH Office of Technology Transfer on or before October 28, 2002 will be considered.

ADDRESSES: Requests for a copy of the patent applications, inquiries, comments and other materials relating to the contemplated license should be directed to: Marlene Shinn, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; Telephone: (301) 496–7056, ext. 285; Facsimile: (301) 402–0220; e-mail: *MS482M@NIH.GOV*.

SUPPLEMENTARY INFORMATION: This technology relates to the results that two derivatives of the potent glucocorticoid dexamethasone show partial agonist activity under a variety of conditions. These steroids have demonstrated affinities for the cell free progesterone receptor that are consistent with their whole cell action arising under conditions where other reported partial progestins were inactive. Of these new antiprogestins that are described in this invention, both Dex-Mes and Dex-ox would be both extremely useful for mechanistic studies in tissue culture systems. Dex-ox is chemically unreactive, while both exhibit considerable amounts of agonist activity under certain circumstances and are partial agonist for glucocorticoid receptors.

The prospective exclusive license will be royalty-bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 22, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–22075 Filed 8–28–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Prospective Grant of Exclusive License: Human Papilloma Virus-Like Particles for the Induction of Autoantibodies

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: This is notice, in accordance with 35 U.S.C. 209(c)(1) and 37 CFR 404.7(a)(1)(i), that the National Institutes of Health (NIH), Department of Health and Human Services, is contemplating the grant of a an exclusive license to practice the invention embodied in: United States Patent Application 09/835,124 and its foreign equivalents entitled ''Virus-Like Particles for the Induction of Autoantibodies'' filed on April 13, 2001, with priority back to U.S. S/N 60/105,132, filed October 21, 1998, to Virionics Corporation, having a place of business in Odenton, Maryland. The patent rights in this invention have been assigned to the United States of America.

DATES: Only written comments and/or application for a license which are received by the NIH Office of Technology Transfer on or before October 28, 2002 will be considered.

ADDRESSES: Requests for a copy of the patent application, inquiries, comments and other materials relating to the contemplated license should be directed to: Peter Soukas, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, MD 20852–3804; e-mail: *ps193c@nih.gov;* Telephone: (301) 496–7056, ext. 268; Facsimile: (301) 402–0220.

SUPPLEMENTARY INFORMATION: This invention claims compositions and methods for producing antibodies to tolerogens (self-antigens normally exposed to B cells that fail to induce an antibody response.) The compositions of the invention comprise multiple copies of a tolerogen (or at least one B cell epitope of a tolerogen) chimerized to capsomeric structures or capsid proteins in an orderly manner. The disclosed compositions can be utilized as prophylactic or therapeutic vaccines against self antigens or antigens of infectious agents. The invention could potentially replace any treatment utilizing chronic administration of a monoclonal antibody that reacts with a self-antigen.

The prospective exclusive license will be royalty bearing and will comply with the terms and conditions of 35 U.S.C. 209 and 37 CFR 404.7. The prospective exclusive license may be granted unless, within 60 days from the date of this published Notice, NIH receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR 404.7.

The field of use may be limited to Human Papilloma Virus-Like Particles vaccines against Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Vascular Endothelial Growth Factor (VEGF) and breast cancer (Her2/neu).

Properly filed competing applications for a license filed in response to this notice will be treated as objections to the contemplated license. Comments and objections submitted in response to this notice will not be made available for public inspection, and, to the extent permitted by law, will not be released under the Freedom of Information Act, 5 U.S.C. 552.

Dated: August 22, 2002.

Jack Spiegel,

Director, Division of Technology Development and Transfer, Office of Technology Transfer.

[FR Doc. 02–22078 Filed 8–28–02; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR–4572–D–26]

Delegation of Authority to the Special Applications Center (SAC) Director

AGENCY: Office of the Assistant Secretary for Public and Indian Housing, HUD.

ACTION: Notice of redelegation of authority.

SUMMARY: In this notice, the Assistant Secretary for Public and Indian Housing redelegates to the Director of the Special Applications Center authority to review and approve or disapprove: (1) Demolition or disposition applications pursuant to section 18 of the United States Housing Act of 1937 and 24 CFR part 970; and (2) agreements for the taking of public housing property in eminent domain proceedings, and conducting all activities related to such review, approval and disapproval with exceptions.

EFFECTIVE DATE: August 12, 2002.

FOR FURTHER INFORMATION CONTACT: Ainars Rodins, Office of Public and Indian Housing, Department of Housing and Urban Development, Special Applications Center, Chicago, IL (312) 353–6236. (This is not a toll-free number.) This number may be accessed via TTY by calling the Federal Information Relay Service at 1–800–877–8339. Comments or questions can be submitted through the Internet to *Ainars_Rodins@hud.gov.*

SUPPLEMENTARY INFORMATION: Under section 18 of the United States Housing Act of 1937 (42 U.S.C. 1437 *et seq.*) (the 1937 Act) the Secretary of Housing and Urban Development has authority to review and approve or disapprove applications from public housing agencies requesting authorization to demolish or dispose of public housing projects or portions of public housing projects. Section 18 is implemented by regulations found at 24 CFR part 970.

Under the Annual Contributions Contract and Declaration of Trust, the Secretary has an interest in public housing projects that require his or her joinder as a party in eminent domain proceedings.

The Secretary has elsewhere delegated to the Assistant Secretary for Public and Indian Housing (PIH) the authority to administer the Department's programs relating to public housing (see the delegation of authority published in the **Federal Register** at 48 FR 41097).

Accordingly, the Assistant Secretary for PIH redelegates that authority, as follows:

Section A: Authority Redelegated

The Assistant Secretary for PIH redelegates the following authority to the Director of the Special Applications Center (SAC), except as provided in Section B. below:

1. To review and approve or disapprove applications for the demolition or disposition of public housing projects pursuant to section 18 of the 1937 Act and the implementing regulations at 24 CFR part 970, and to conduct all activities related to such review, and approval or disapproval of such applications.

2. To review and approve or disapprove agreements for the taking of public housing property in eminent domain proceedings and conduct all activities related to such review, and approval or disapproval of such agreements.

Section B: Authority Excepted

1. The authority redelegated does not include the authority to waive regulations; and

2. The Director of the SAC may exercise the authority to disapprove an application for demolition or disposition or an agreement for the taking of public housing property in eminent domain proceedings on the grounds that the application or agreement is prohibited by or inconsistent with applicable Federal law only with the concurrence of the Assistant Secretary for PIH or his or her designee.

Section C: Authority to Further Redelegate

The authority redelegated in Section A may not be further redelegated except to an official authorized to act for the Director of the SAC in his or her absence.

Section D: Authority Revoked

The redelegation of authority from the Assistant Secretary for PIH to PIH Directors and Deputy Directors in the field, published in the **Federal Register** at 59 FR 51200 (October 7, 1994) is revoked in part. Specifically, the authority redelegated to PIH Directors and Deputy Directors with regard to demolition and disposition of public housing (section 18 of the 1937 Act and implementing regulations at 24 CFR part 970) is revoked (see Section C.(2) of the October 7, 1994 redelegation). The redelegation of authority to PIH Directors and Deputy Directors remains otherwise in effect.

Dated: August 12, 2002.

Michael Liu,

Assistant Secretary for Public and Indian Housing.

[FR Doc. 02–21986 Filed 8–28–02; 8:45 am]

BILLING CODE 4210–33–P

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Information Collection To Be Submitted to the Office of Management and Budget (OMB) for Approval Under the Paperwork Reduction Act

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice; request for comments.

SUMMARY: The U.S. Fish and Wildlife Service will submit the collection of information listed below to OMB for approval under the provisions of the Paperwork Reduction Act. A copy of the information collection requirement is included in this notice. If you wish to obtain copies of the proposed information collection requirement, related forms, and explanatory material, contact the Service Information Collection Clearance Officer at the address listed below.